Cargando…

Evaluating the benefits of neoadjuvant chemotherapy for advanced epithelial ovarian cancer: a retrospective study

OBJECTIVE: To compare the chemoresistance and survival in patients with stage IIIC or IV epithelial ovarian cancer who were treated with neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) or primary debulking surgery (PDS). The clinical characteristics of patients who benef...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gao, Yan, Li, Yuan, Zhang, Chunyu, Han, Jinsong, Liang, Huamao, Zhang, Kun, Guo, Hongyan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6744704/ https://www.ncbi.nlm.nih.gov/pubmed/31519183 http://dx.doi.org/10.1186/s13048-019-0562-9

Ejemplares similares

Feasibility and outcome of primary laparoscopic cytoreductive surgery for advanced epithelial ovarian cancer: a comparison to laparotomic surgery in retrospective cohorts
por: Liang, Huamao, et al.
Publicado: (2017)

Associations of novel serum lipid index with epithelial ovarian cancer chemoresistance and prognosis
por: Li, Yuan, et al.
Publicado: (2023)

Neoadjuvant chemotherapy in advanced epithelial ovarian cancer: A survival study
por: Baruah, Upasana, et al.
Publicado: (2015)

Neoadjuvant chemotherapy for Patients with advanced epithelial ovarian cancer: A Meta-Analysis
por: Zeng, Long-Jia, et al.
Publicado: (2016)

The role of neoadjuvant chemotherapy in patients with advanced (stage IIIC) epithelial ovarian cancer
por: Škof, Erik, et al.
Publicado: (2016)

Tumor immune microenvironment changes are associated with response to neoadjuvant chemotherapy and long-term survival benefits in advanced epithelial ovarian cancer: A pilot study
por: Cao, Guangming, et al.
Publicado: (2023)

AEG-1 as a predictor of sensitivity to neoadjuvant chemotherapy in advanced epithelial ovarian cancer
por: Wang, Yao, et al.
Publicado: (2016)

Incidence of venous thromboembolism following the neoadjuvant chemotherapy regimen for epithelial type of ovarian cancer
por: Chavan, Devendra Manik, et al.
Publicado: (2017)

Neoadjuvant chemotherapy in advanced epithelial ovarian cancer by histology: A SEER based survival analysis
por: Liu, Yuexi, et al.
Publicado: (2023)

Prognostic Factors for Advanced Epithelial Ovarian Cancer Following Primary Cytoreductive Surgery or Neoadjuvant Chemotherapy
por: Nantasupha, Chalaithorn, et al.
Publicado: (2022)

Post-operative residual disease and number of cycles of neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma
por: Perrone, Anna Myriam, et al.
Publicado: (2023)

Feasibility of neoadjuvant and adjuvant intraperitoneal chemotherapy in patients with advanced epithelial ovarian cancer: A single-center experience
por: Liu, Yu, et al.
Publicado: (2020)

Neoadjuvant chemotherapy versus primary debulking surgery in advanced epithelial ovarian cancer: A meta-analysis of peri-operative outcome
por: Yang, Lijuan, et al.
Publicado: (2017)

Clinical benefit and tolerability of adjuvant intraperitoneal chemotherapy in patients who have or have not received neoadjuvant chemotherapy for advanced ovarian cancer
por: Meghal, Trishala, et al.
Publicado: (2019)

Survival Effects of Cytoreductive Surgery for Refractory Patients after Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer
por: Shin, Wonkyo, et al.
Publicado: (2020)

Neoadjuvant chemotherapy followed by interval debulking surgery for advanced epithelial ovarian cancer: GOTIC-019 study
por: Nagao, Shoji, et al.
Publicado: (2023)

Neoadjuvant nimotuzumab plus chemoradiotherapy compared to neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma
por: Chen, Yongshun, et al.
Publicado: (2018)

Neoadjuvant chemotherapy versus primary surgery in advanced ovarian carcinoma
por: Hegazy, Mohamed AF, et al.
Publicado: (2005)

Neoadjuvant chemotherapy in advanced-stage ovarian cancer – state of the art
por: Margioula-Siarkou, Chrysoula, et al.
Publicado: (2022)

Addendum: Neoadjuvant nimotuzumab plus chemoradiotherapy compared to neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma
por: Chen, Yongshun, et al.
Publicado: (2022)

Clinical Impact of Lymphadenectomy after Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer: A Review of Available Data
por: Seidler, Stephanie, et al.
Publicado: (2021)

Kinetics of HE4 and CA125 as prognosis biomarkers during neoadjuvant chemotherapy in advanced epithelial ovarian cancer
por: Alegría-Baños, Jorge A., et al.
Publicado: (2021)

The prognostic effect of residual tumor for advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy or primary debulking surgery
por: Yang, Shi‐Ping, et al.
Publicado: (2022)

Timing of interval debulking surgery and postoperative chemotherapy after neoadjuvant chemotherapy in advanced epithelial ovarian cancer: a multicenter real-world study
por: Liu, Xingyu, et al.
Publicado: (2023)

Cross-validation of genes potentially associated with neoadjuvant chemotherapy and platinum-based chemoresistance in epithelial ovarian carcinoma
por: Zhang, Kai, et al.
Publicado: (2020)

Comparison of adjuvant and neoadjuvant chemotherapy in the management of advanced ovarian cancer: a retrospective study of 574 patients
por: Inciura, Arturas, et al.
Publicado: (2006)

Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer
por: Luo, Yanlin, et al.
Publicado: (2016)

Neoadjuvant chemotherapy for epithelial ovarian cancer in Japan: a JSGO-JSOG joint study
por: Machida, Hiroko, et al.
Publicado: (2019)

Efficacy evaluation of albumin-bound paclitaxel combined with carboplatin as neoadjuvant chemotherapy for primary epithelial ovarian cancer
por: Wang, Huan, et al.
Publicado: (2022)

GEN-1 in Combination with Neoadjuvant Chemotherapy for Patients with Advanced Epithelial Ovarian Cancer: A Phase I Dose-escalation Study
por: Thaker, Premal H., et al.
Publicado: (2021)

Effect of neoadjuvant chemotherapy combined with hyperthermic intraperitoneal perfusion chemotherapy on advanced gastric cancer
por: CUI, HAI-BIN, et al.
Publicado: (2014)

Genomic landscape and immune-related gene expression profiling of epithelial ovarian cancer after neoadjuvant chemotherapy
por: Lodewijk, I., et al.
Publicado: (2022)

Overexpression of DUSP6 enhances chemotherapy-resistance of ovarian epithelial cancer by regulating the ERK signaling pathway
por: Gao, Yan, et al.
Publicado: (2020)

Uptake and Outcomes of Neoadjuvant Chemotherapy Among US Patients With Less Common Epithelial Ovarian Carcinomas
por: Matsuo, Koji, et al.
Publicado: (2023)

Impact of neoadjuvant chemotherapy and postoperative adjuvant chemotherapy cycles on survival of patients with advanced-stage ovarian cancer
por: Chung, Young Shin, et al.
Publicado: (2017)

Emerging Trends in Neoadjuvant Chemotherapy for Ovarian Cancer
por: Patel, Ami, et al.
Publicado: (2021)

A Retrospective Study of Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer
por: Wang, Yajing, et al.
Publicado: (2020)

Establishment of an optimized CTC detection model consisting of EpCAM, MUC1 and WT1 in epithelial ovarian cancer and its correlation with clinical characteristics
por: Wang, Tongxia, et al.
Publicado: (2022)

Activation of hedgehog signaling and its association with cisplatin resistance in ovarian epithelial tumors
por: Song, Xueling, et al.
Publicado: (2018)

Neoadjuvant chemotherapy alters the balance of effector to suppressor immune cells in advanced ovarian cancer
por: Leary, Alexandra, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hfkk18ucme3pchsmbja4spr93a